A sustainable business model based on innovation and ... - Roche

More documents

Recommendations

Info

Comprehensive development program in RA Covers all treatment stages MabThera IMAGE** (MTX naive, X-ray study) SERENE* (MTX IR) MIRROR* (MTX IR, dose escalation) REFLEX (Anti-TNF IR) SCORE** (DMARDs IR) current Tx paradigm NSAIDs or Cox-2 DMARDs TNF inhibitors 2 nd biologic (+/- MTX) (+/- MTX) OPTION* (MTX IR) Actemra AMBITION* (6 mnth MTX free/ MTX naive, monotherapy) TOWARD* (DMARDs IR) LITHE** (MTX IR, X-ray study) RADIATE* (Anti-TNF IR) * Indication not yet approved, awaiting regulatory approval ** Phase III trial in progress 28
Performance up-date Strategy Main trends influencing long term value propositions Summary 29
Page 1 and 2: Roche A sustainable</strong
Page 3 and 4: Performance up-date Strategy Main t
Page 5 and 6: Performance up-date Our Strategy an
Page 7 and 8: Focus on our core business<
Page 9 and 10: Not to invest in the future means b
Page 11 and 12: Responsible management of R&D spend
Page 13 and 14: Main trends influencing the long-te
Page 15 and 16: Scenarios for PHC Added Value Distr
Page 17 and 18: Key drivers for long term developme
Page 19 and 20: Major growth opportunities outside
Page 21 and 22: First in class mechanisms establish
Page 23 and 24: Avastin: significant potential for
Page 25 and 26: ASCO 2009 Highlights Avastin NSABP
Page 27: Rheumatoid Arthritis: Not all patie
Page 31 and 32: Profitability measures Operating ca
Page 33 and 34: Patent expiry 2008-2012 Roche short
Page 35 and 36: We Innovate Healthcare 35
Page 37: Top 10 Oncology Products Sales and

A sustainable business model based on innovation and ... - Roche

Create successful ePaper yourself

Delete template?

Save as template?